3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Leukemia, B-Cell
2
Leukemia
2
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
100
Rituximab
82
fludarabine phosphate
46
Peripheral Blood Stem Cell Transplantation
45
fludarabine
43
Lenalidomide
35
Filgrastim
33
Methotrexate
32
Cytarabine
32
Busulfan
32
venetoclax
31
Etoposide
31
Cyclosporine
30
Dexamethasone
29
Radiotherapy
28
Mycophenolic Acid
28
Melphalan
28
Bendamustine Hydrochloride
25
Antilymphocyte Serum
25
Vincristine
24
Gemcitabine
24
ibrutinib
22
Whole-Body Irradiation
22
Doxorubicin
20
Tacrolimus
19
Methylprednisolone
18
Bortezomib
18
Brentuximab Vedotin
16
pembrolizumab
15
Prednisone
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
navitoclax
×
Lymphoid
×
Clear all
NCT05740449
2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2
Withdrawn